Acenocoumarol
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| |
| Acenocoumarol
| |
| Systematic (IUPAC) name | |
| 2-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-4H- chromen-4-one | |
| Identifiers | |
| CAS number | |
| ATC code | B01 |
| PubChem | |
| Chemical data | |
| Formula | C19H15NO6 |
| Mol. mass | 353.326 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | Hepatic |
| Half life | 8 to 11 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
|
WikiDoc Resources for Acenocoumarol | |
|
Articles | |
|---|---|
|
Most recent articles on Acenocoumarol Most cited articles on Acenocoumarol | |
|
Media | |
|
Powerpoint slides on Acenocoumarol | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Acenocoumarol at Clinical Trials.gov Trial results on Acenocoumarol Clinical Trials on Acenocoumarol at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Acenocoumarol NICE Guidance on Acenocoumarol
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Acenocoumarol Discussion groups on Acenocoumarol Patient Handouts on Acenocoumarol Directions to Hospitals Treating Acenocoumarol Risk calculators and risk factors for Acenocoumarol
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Acenocoumarol | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin).
It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome®.
External links
- DDB 29202
- Cesar J, García-Avello A, Navarro J, Herraez M (2004). "Aging and oral anticoagulant therapy using acenocoumarol.". Blood Coagul Fibrinolysis 15 (8): 673-6. PMID 15613922.
- Lengyel M (2004). "Warfarin or acenocoumarol is better in the anticoagulant treatment of chronic atrial fibrillation?". Orv Hetil 145 (52): 2619-21. PMID 15724697.
- Ufer M (2005). "Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.". Clin Pharmacokinet 44 (12): 1227-46. PMID 16372822.
- Montes R, Ruiz de Gaona E, Martínez-González M, Alberca I, Hermida J (2006). "The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients.". Br J Haematol 133 (2): 183-7. PMID 16611310.
| ||||
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
